Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer Complex

PLoS Pathogens

Volumn 10, Issue 11, 2014, Pages

  Wussow, Felix ^a   Chiuppesi, Flavia ^a   Martinez, Joy ^a   Campo, John ^a   Johnson, Erica ^b   Flechsig, Christin ^a   Newell, Maegan ^a   Tran, Elaine ^a   Ortiz, Jose ^a   La Rosa, Corinna ^a   Herrmann, Andreas ^a   Longmate, Jeff ^a   Chakraborty, Rana ^b   Barry, Peter A ^c   Diamond, Don J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CYTOMEGALOVIRUS VACCINE; EPITOPE; GLYCOPROTEIN; GLYCOPROTEIN H; GLYCOPROTEIN L; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS E ANTIGEN; MULTIPROTEIN COMPLEX; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CYTOMEGALOVIRUS; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MACROPHAGE; MOLECULAR CLONING; MOUSE; MUTAGENESIS; NONHUMAN; ORAL BIOPSY; PLACENTA; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RHESUS MONKEY; SECRETION (PROCESS); SERODIAGNOSIS; VACCINATION; VACCINIA VIRUS; VIRUS ENVELOPE; VIRUS PARTICLE; ANIMAL; BAGG ALBINO MOUSE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GENETICS; IMMUNOLOGY;

HUMAN HERPESVIRUS 5;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; FEMALE; HUMANS; MACACA MULATTA; MICE; MICE, INBRED BALB C; MULTIPROTEIN COMPLEXES; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 84912121233     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004524     Document Type: Article

References (112)

1. Plotkin SA, (1999) Vaccination against cytomegalovirus, the changeling demon. Pediatr Infect Dis J 18: 313–325.
2. Weller TH, (1971) The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. II. N Engl J Med 285: 267–274.
3. Pereira L, Maidji E, (2008) Cytomegalovirus infection in the human placenta: maternal immunity and developmentally regulated receptors on trophoblasts converge. Curr Top Microbiol Immunol 325: 383–395.
4. Griffiths P, Plotkin S, Mocarski E, Pass R, Schleiss M, Krause P, Bialek S, (2013) Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine 31 Suppl 2: B197–B203.
5. Schleiss MR, (2013) Cytomegalovirus in the Neonate: Immune Correlates of Infection and Protection. Clin Dev Immunol 2013: 501801.
6. Stratton KR, Durch JS, Lawrence RS (2001) Vaccines for the 21st Century: A tool for Decisionmaking. Bethesda: National Academy Press. 476 p.
7. Lilja AE, Mason PW, (2012) The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB. Vaccine 30: 6980–6990.
8. Krause PR, Bialek SR, Boppana SB, Griffiths PD, Laughlin CA, et al. (2013) Priorities for CMV vaccine development. Vaccine 32: 4–10.
9. Plotkin SA, (2010) Correlates of protection induced by vaccination. Clin Vaccine Immunol 17: 1055–1065.
10. Schiller JT, Castellsague X, Villa LL, Hildesheim A, (2008) An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26 Suppl 10: K53–K61.
11. Keating GM, Noble S, (2003) Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs. 63: 1021–1051.
12. Nigro G, Adler SP, La Torre R, Best AM, (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353: 1350–1362.
13. Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, et al. (2014) A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 370: 1316–1326.
14. Corti D, Lanzavecchia A, (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31: 705–742.
15. Rasmussen L, Matkin C, Spaete R, Pachl C, Merigan TC, (1991) Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J Infect Dis 164: 835–842.
16. Marshall GS, Stout GG, Knights ME, Rabalais GP, Ashley R, et al. (1994) Ontogeny of glycoprotein gB-specific antibody and neutralizing activity during natural cytomegalovirus infection. J Med Virol 43: 77–83.
17. Isaacson MK, Compton T, (2009) Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. J Virol 83: 3891–3903.
18. Kinzler ER, Compton T, (2005) Characterization of human cytomegalovirus glycoprotein-induced cell-cell fusion. J Virol 79: 7827–7837.
19. Navarro D, Paz P, Tugizov S, Topp K, La Vail J, et al. (1993) Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology 197: 143–158.
20. Britt WJ, (1984) Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology 135: 369–378.
21. Britt WJ, Vugler L, Stephens EB, (1988) Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB). J Virol 62: 3309–3318.
22. Gonczol E, Ianacone J, Ho WZ, Starr S, Meignier B, et al. (1990) Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 8: 130–136.
23. Liu YN, Klaus A, Kari B, Stinski MF, Eckhardt J, et al. (1991) The N-terminal 513 amino acids of the envelope glycoprotein gB of human cytomegalovirus stimulates both B- and T-cell immune responses in humans. J Virol 65: 1644–1648.
24. Boppana SB, Britt WJ, (1995) Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 171: 1115–1121.
25. de Vries JJ, van Zwet EW, Dekker FW, Kroes AC, Verkerk PH, et al. (2013) The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population-based prediction model. Rev Med Virol 23: 241–249.
26. Fowler KB, Stagno S, Pass RF, (2003) Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 289: 1008–1011.
27. Pass RF, Duliege AM, Boppana S, Sekulovich R, Percell S, et al. (1999) A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 180: 970–975.
28. Pass RF, (2009) Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant. J Clin Virol 46 Suppl 4: S73–S76.
29. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, et al. (2009) Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360: 1191–1199.
30. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, et al. (2011) Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377: 1256–1263.
31. Gerna G, Sarasini A, Patrone M, Percivalle E, Fiorina L, et al. (2008) Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol 89: 853–865.
32. Straschewski S, Patrone M, Walther P, Gallina A, Mertens T, et al. (2011) Protein pUL128 of Human Cytomegalovirus Is Necessary for Monocyte Infection and Blocking of Migration. J Virol 85: 5150–5158.
33. Wang D, Shenk T, (2005) Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A 102: 18153–18158.
34. Vanarsdall AL, Ryckman BJ, Chase MC, Johnson DC, (2008) Human cytomegalovirus glycoproteins gB and gH/gL mediate epithelial cell-cell fusion when expressed either in cis or in trans. J Virol 82: 11837–11850.
35. Fouts AE, Comps-Agrar L, Stengel KF, Ellerman D, Schoeffler AJ, et al. (2014) Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109. Proc Natl Acad Sci U S A 111: 8209–8214.
36. Vanarsdall AL, Chase MC, Johnson DC, (2011) Human cytomegalovirus glycoprotein gO complexes with gH/gL, promoting interference with viral entry into human fibroblasts but not entry into epithelial cells. J Virol 85: 11638–11645.
37. Vanarsdall AL, Johnson DC, (2012) Human cytomegalovirus entry into cells. Curr Opin Virol 2: 37–42.
38. Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, et al. (2004) Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78: 10023–10033.
39. Ryckman BJ, Rainish BL, Chase MC, Borton JA, Nelson JA, et al. (2008) Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J Virol 82: 60–70.
40. Cui X, Meza BP, Adler SP, McVoy MA, (2008) Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26: 5760–5766.
41. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, et al. (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84: 1005–1013.
42. Genini E, Percivalle E, Sarasini A, Revello MG, Baldanti F, et al. (2011) Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J Clin Virol 52: 113–118.
43. Fu TM, Wang D, Freed DC, Tang A, Li F, et al. (2012) Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus. Vaccine 30: 7469–7474.
44. Fouts AE, Chan P, Stephan JP, Vandlen R, Feierbach B, (2012) Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol 86: 7444–7447.
45. Lilleri D, Kabanova A, Lanzavecchia A, Gerna G, (2012) Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J Clin Immunol 32: 1324–1331.
46. Wussow F, Yue Y, Martinez J, Deere JD, Longmate J, et al. (2013) A Vaccine Based on the Rhesus Cytomegalovirus UL128 Complex Induces Broadly Neutralizing Antibodies in Rhesus Macaques. J Virol 87: 1322–1332.
47. Sinzger C, Digel M, Jahn G, (2008) Cytomegalovirus cell tropism. Curr Top Microbiol Immunol 325: 63–83.
48. Tang Z, Tadesse S, Norwitz E, Mor G, Abrahams VM, et al. (2011) Isolation of hofbauer cells from human term placentas with high yield and purity. Am J Reprod Immunol 66: 336–348.
49. Sinzger C, Hahn G, Digel M, Katona R, Sampaio KL, et al. (2008) Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J Gen Virol 89: 359–368.
50. Ryckman BJ, Chase MC, Johnson DC, (2010) Human cytomegalovirus TR strain glycoprotein O acts as a chaperone promoting gH/gL incorporation into virions but is not present in virions. J Virol 84: 2597–2609.
51. Zhou M, Yu Q, Wechsler A, Ryckman BJ, (2013) Comparative analysis of gO isoforms reveals that strains of human cytomegalovirus differ in the ratio of gH/gL/gO and gH/gL/UL128-131 in the virion envelope. J Virol 87: 9680–9690.
52. Wyatt LS, Earl PL, Xiao W, Americo JL, Cotter CA, et al. (2009) Elucidating and minimizing the loss by recombinant vaccinia virus of human immunodeficiency virus gene expression resulting from spontaneous mutations and positive selection. J Virol 83: 7176–7184.
53. Wang Z, La Rosa C, Maas R, Ly H, Brewer J, et al. (2004) Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J Virol 78: 3965–3976.
54. Endresz V, Burian K, Berencsi K, Gyulai Z, Kari L, et al. (2001) Optimization of DNA immunization against human cytomegalovirus. Vaccine 19: 3972–3980.
55. Adler B, Scrivano L, Ruzcics Z, Rupp B, Sinzger C, et al. (2006) Role of human cytomegalovirus UL131A in cell type-specific virus entry and release. J Gen Virol 87: 2451–2460.
56. Patrone M, Secchi M, Fiorina L, Ierardi M, Milanesi G, et al. (2005) Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion. J Virol 79: 8361–8373.
57. Schmelz M, Sodeik B, Ericsson M, Wolffe EJ, Shida H, et al. (1994) Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J Virol 68: 130–147.
58. Wang Z, Martinez J, Zhou W, La Rosa C, Srivastava T, et al. (2010) Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine 28: 1547–1557.
59. Simpson JA, Chow JC, Baker J, Avdalovic N, Yuan S, et al. (1993) Neutralizing monoclonal antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites. J Virol 67: 489–496.
60. Cottingham MG, Andersen RF, Spencer AJ, Saurya S, Furze J, et al. (2008) Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS ONE 3: e1638.
61. Baldanti F, Paolucci S, Campanini G, Sarasini A, Percivalle E, et al. (2006) Human cytomegalovirus UL131A, UL130 and UL128 genes are highly conserved among field isolates. Arch Virol 151: 1225–1233.
62. Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, Johnson DC, (2006) Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol 80: 710–722.
63. Waldman WJ, Roberts WH, Davis DH, Williams MV, Sedmak DD, et al. (1991) Preservation of natural endothelial cytopathogenicity of cytomegalovirus by propagation in endothelial cells. Arch Virol 117: 143–164.
64. Siewiera J, El Costa H, Tabiasco J, Berrebi A, Cartron G, et al. (2013) Human cytomegalovirus infection elicits new decidual natural killer cell effector functions. PLoS Pathog 9: e1003257.
65. Wang D, Li F, Freed DC, Finnefrock AC, Tang A, et al. (2011) Quantitative analysis of neutralizing antibody response to human cytomegalovirus in natural infection. Vaccine 29: 9075–9080.
66. Loomis RJ, Lilja AE, Monroe J, Balabanis KA, Brito LA, et al. (2013) Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies. Vaccine 31: 919–926.
67. Bacsi A, Aranyosi J, Beck Z, Ebbesen P, Andirko I, et al. (1999) Placental macrophage contact potentiates the complete replicative cycle of human cytomegalovirus in syncytiotrophoblast cells: role of interleukin-8 and transforming growth factor-beta1. J Interferon Cytokine Res 19: 1153–1160.
68. Sinzger C, Muntefering H, Loning T, Stoss H, Plachter B, et al. (1993) Cell types infected in human cytomegalovirus placentitis identified by immunohistochemical double staining. Virchows Arch A Pathol Anat Histopathol 423: 249–256.
69. Schwartz DA, Khan R, Stoll B, (1992) Characterization of the fetal inflammatory response to cytomegalovirus placentitis. An immunohistochemical study. Arch Pathol Lab Med 116: 21–27.
70. Maidji E, McDonagh S, Genbacev O, Tabata T, Pereira L, (2006) Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am J Pathol 168: 1210–1226.
71. Weisblum Y, Panet A, Zakay-Rones Z, Haimov-Kochman R, Goldman-Wohl D, et al. (2011) Modeling of human cytomegalovirus maternal-fetal transmission in a novel decidual organ culture. J Virol 85: 13204–13213.
72. Satosar A, Ramirez NC, Bartholomew D, Davis J, Nuovo GJ, (2004) Histologic correlates of viral and bacterial infection of the placenta associated with severe morbidity and mortality in the newborn. Hum Pathol 35: 536–545.
73. Saccoccio FM, Gallagher MK, Adler SP, McVoy MA, (2011) Neutralizing activity of saliva against cytomegalovirus. Clin Vaccine Immunol 18: 1536–1542.
74. Brandtzaeg P, (2007) Do salivary antibodies reliably reflect both mucosal and systemic immunity? Ann N Y Acad Sci 1098: 288–311.
75. Furione M, Rognoni V, Sarasini A, Zavattoni M, Lilleri D, et al. (2013) Slow increase in IgG avidity correlates with prevention of human cytomegalovirus transmission to the fetus. J Med Virol 85: 1960–1967.
76. Prince HE, Leber AL, (2002) Validation of an in-house assay for cytomegalovirus immunoglobulin G (CMV IgG) avidity and relationship of avidity to CMV IgM levels. Clin Diagn Lab Immunol 9: 824–827.
77. Marshall BC, Adler SP, (2003) Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59). Viral Immunol 16: 491–500.
78. Pereira L, Maidji E, McDonagh S, Tabata T, (2005) Insights into viral transmission at the uterine-placental interface. Trends Microbiol 13: 164–174.
79. Lauron EJ, Yu D, Fehr AR, Hertel L, (2014) Human cytomegalovirus infection of langerhans-type dendritic cells does not require the presence of the gH/gL/UL128-131A complex and is blocked after nuclear deposition of viral genomes in immature cells. J Virol 88: 403–416.
80. Dunn W, Chou C, Li H, Hai R, Patterson D, et al. (2003) Functional profiling of a human cytomegalovirus genome. Proc Natl Acad Sci U S A 100: 14223–14228.
81. Endresz V, Kari L, Berencsi K, Kari C, Gyulai Z, et al. (1999) Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine 17: 50–58.
82. Britt WJ, Vugler LG, (1989) Processing of the gp55-116 envelope glycoprotein complex (gB) of human cytomegalovirus. J Virol 63: 403–410.
83. Spaete RR, Thayer RM, Probert WS, Masiarz FR, Chamberlain SH, et al. (1988) Human cytomegalovirus strain Towne glycoprotein B is processed by proteolytic cleavage. Virology 167: 207–225.
84. Gonczol E, Berensci K, Pincus S, Endresz V, Meric C, et al. (1995) Preclinical evaluation of an ALVAC (canarypox)—human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 13: 1080–1085.
85. Kaur A, Barry PA, Bialas K, Tran D, Varner V, et al. (2013) Successful development of a nonhuman primate model of congenital cytomegalovirus transmission. 31st Annual Symposium on Nonhuman Primate Models for AIDS.
86. Cayatte C, Schneider-Ohrum K, Wang Z, Irrinki A, Nguyen N, et al. (2013) Cytomegalovirus Vaccine Strain Towne-Derived Dense Bodies Induce Broad Cellular Immune Responses and Neutralizing Antibodies That Prevent Infection of Fibroblasts and Epithelial Cells. Journal of Virology 87: 11107–11120.
87. Kovacs JM, Nkolola JP, Peng H, Cheung A, Perry J, et al. (2012) HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. Proc Natl Acad Sci U S A 109: 12111–12116.
88. Wen Y, Monroe J, Linton C, Archer J, Beard CW, et al. (2014) Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine 32: 3796–804.
89. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233–236.
90. Yue Y, Barry PA, (2008) Rhesus cytomegalovirus a nonhuman primate model for the study of human cytomegalovirus. Adv Virus Res 72: 207–226.
91. Barry PA, Strelow L, (2008) Development of breeding populations of rhesus macaques (Macaca mulatta) that are specific pathogen-free for rhesus cytomegalovirus. Comp Med 58: 43–46.
92. Abel K, Martinez J, Yue Y, Lacey SF, Wang Z, et al. (2010) Vaccine-Induced Control of Viral Shedding Following Rhesus Cytomegalovirus Challenge in Rhesus Macaques. J Virol 85: 2878–2890.
93. Walsh SR, Seaman MS, Grandpre LE, Charbonneau C, Yanosick KE, et al. (2012) Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses. Vaccine 31: 114–119.
94. Wilck MB, Seaman MS, Baden LR, Walsh SR, Grandpre LE, et al. (2010) Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration. J Infect Dis 201: 1361–1370.
95. Pass RF, Little EA, Stagno S, Britt WJ, Alford CA, (1987) Young children as a probable source of maternal and congenital cytomegalovirus infection. N Engl J Med 316: 1366–1370.
96. Adler SP, (1989) Cytomegalovirus and child day care. Evidence for an increased infection rate among day-care workers. N Engl J Med 321: 1290–1296.
97. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ, (2001) Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med 344: 1366–1371.
98. Abel K, Martinez J, Yue Y, Lacey SF, Wang Z, et al. (2011) Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques. J Virol 85: 2878–2890.
99. Sampaio KL, Cavignac Y, Stierhof YD, Sinzger C, (2005) Human cytomegalovirus labeled with green fluorescent protein for live analysis of intracellular particle movements. J Virol 79: 2754–2767.
100. Johnson EL, Chakraborty R, (2012) Placental Hofbauer cells limit HIV-1 replication and potentially offset mother to child transmission (MTCT) by induction of immunoregulatory cytokines. Retrovirology 9: 101.
101. Earl PL, Moss B, Wyatt LS, Carroll MW, (2001) Generation of recombinant vaccinia viruses. Curr Protoc Protein Sci Chapter 5: Unit5.
102. Manuel ER, Wang Z, Li Z, La Rosa C, Zhou W, et al. (2010) Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses. Virology 403: 155–162.
103. Tischer BK, Smith GA, Osterrieder N, (2010) En passant mutagenesis: a two step markerless red recombination system. Methods Mol Biol 634: 421–430.
104. Tischer BK, Kaufer BB, Sommer M, Wussow F, Arvin AM, et al. (2007) A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein encoded by ORF9. J Virol 81: 13200–13208.
105. Tischer BK, von Einem J, Kaufer B, Osterrieder N, (2006) Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40: 191–197.
106. Spaete RR, (1991) A recombinant subunit vaccine approach to HCMV vaccine development. Transplantation Proceedings 23: 90–96.
107. Mayr A, Malicki K, (1966) [Attenuation of virulent fowl pox virus in tissue culture and characteristics of the attenuated virus]. Zentralbl Veterinarmed B 13: 1–13.
108. Domi A, Moss B, (2002) Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci U S A 99: 12415–12420.
109. Birnboim HC, Doly J, (1979) A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res 7: 1513–1523.
110. Andreoni M, Faircloth M, Vugler L, Britt WJ, (1989) A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J Virol Methods 23: 157–167.
111. Yue Y, Wang Z, Abel K, Li J, Strelow L, et al. (2008) Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques. Med Microbiol Immunol 197: 117–123.
112. Britt WJ, Jarvis MA, Drummond DD, Mach M, (2005) Antigenic domain 1 is required for oligomerization of human cytomegalovirus glycoprotein B. J Virol. 79: 4066–4079.